#Italy #Milan #Hansoh Pharma #EASD #Olatorepatide

Olatorepatide: A Novel Approach in Weight Management

The annual European Association for the Study of Diabetes (EASD) meeting took place in Milan from September 28 to October 2, 2026, attracting attention from across the globe. Among the intriguing presentations was that of Olatorepatide (HS-20094), a dual-action agonist targeting GLP-1 and GIP receptors, developed by Hansoh Pharma.

Olatorepatide's phase III study, named LIGHTEN, demonstrates significant efficacy for weight management, showcasing an average weight loss of 19.3% at the 48-week mark for participants receiving 15 mg doses without reaching a plateau. This novel therapy places a strong emphasis on both effectiveness and gastrointestinal tolerability, a frequent concern associated with many weight loss medications.

The LIGHTEN study was conducted as a multicenter, randomized, double-blind, placebo-controlled trial across China, enrolling 604 adults suffering from overweight or obesity, defined by a Body Mass Index (BMI) of 28 kg/m² or higher. Participants were divided to receive subcutaneous injections of Olatorepatide in various doses (5 mg, 10 mg, or 15 mg) or a placebo over a 48-week span.

Results Breakdown

Primary Efficacy Outcomes

Primary outcomes included the percentage change in body weight from baseline to week 48 and the proportion of participants achieving a weight loss of at least 5%. Remarkably, the results indicated that 90.1% of participants completed all treatments within the designated 48 weeks. Here’s how the data shaped up based on different doses:

• - Weight Loss Achievements:

- 5 mg Group: Average weight loss of 12.5%
- 10 mg Group: Average weight loss of 17.5%
- 15 mg Group: Average weight loss of 19.3%

• - Placebo Group: Achieved a mere 2.7% weight loss

Statistically significant differences were noted across all dosages when compared to the placebo (P < 0.0001).

Furthermore, the proportions of participants achieving clinically relevant weight loss milestones were notable: 87.3%, 97.2%, and 95.2% for 5 mg, 10 mg, and 15 mg groups respectively, compared to only 28.6% in the placebo cohort for a weight loss of 5% or more. Higher thresholds of 10% and 15% also reflected a marked improvement over placebo, thus projecting the medication's potential for effective weight management.

Waist Circumference Reduction

In addition to weight loss, waist circumference also displayed significant declines:

• - 5 mg Group: 10.5 cm reduction
• - 10 mg Group: 14.4 cm reduction
• - 15 mg Group: 16.0 cm reduction
• - Placebo Group: 3.6 cm reduction

All reductions between the treatment groups were statistically significant (P < 0.0001).

Metabolic Profile Improvements

Not just weight loss, but Olatorepatide also improved crucial metabolic parameters, including reductions in blood pressure, serum lipids, hemoglobin A1c (HbA1c), and other metabolic syndrome markers—demonstrating a comprehensive benefit profile.

Safety and Tolerability

In terms of safety, the side effect profile of Olatorepatide was comparable to other established incretin-based treatments with a notable decrease in the frequency of gastrointestinal adverse events. For instance, the incidence of nausea and vomiting was reported at 7.8% and 4.9% respectively, signaling an improvement over other available therapies. Importantly, no study participants discontinued their treatment due to adverse effects from Olatorepatide.

This reflects a promising clinical pathway for Olatorepatide as a favorable alternative in weight management strategies, showing a solid standing in a space rife with medication inefficacies. The ongoing phase III trials also extend to its applicability in managing Type 2 diabetes, which may open up further therapeutic avenues for patients.

Conclusion

The EASD meeting highlighted Olatorepatide's potential as a breakthrough therapeutic approach in managing obesity while addressing tolerability issues often seen with existing treatments. The recognition by the global scientific community, emphasized by the Late-breaking Abstract presentation, showcases the credibility and relevancy of the findings within clinical practice, indicating a brighter future for obesity management with Olatorepatide at the forefront. As the pharmaceutical landscape continues to evolve, Hansoh Pharma aims to deliver innovation that significantly improves health outcomes, resonating with its mission of continuous innovation for better lives.